Economic issues and the management of benign prostatic hyperplasia

H L Holtgrewe1

  • 1Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Urology
|September 1, 1995
PubMed

Insights

Benign prostatic hyperplasia (BPH) treatment incurs significant costs. Following US clinical guidelines for BPH diagnosis and management can lead to substantial financial savings without compromising patient care quality.

Area of Science:

  • Urology
  • Health Economics

Background:

  • Benign prostatic hyperplasia (BPH) causes significant urologic symptoms and complications, leading to substantial global healthcare expenditures.
  • Accurate documentation of financial spending on BPH management, particularly surgical interventions, is lacking internationally.

Purpose of the Study:

  • To evaluate the potential financial savings achievable by adhering to established clinical guidelines for BPH diagnosis and management.
  • To assess the impact of guideline adherence on the quality of patient care.

Main Methods:

  • Review of US Department of Health and Human Services clinical guidelines for BPH (released February 8, 1994).
  • Analysis of guideline recommendations regarding routine imaging of the upper urinary tract and diagnostic cystoscopy.
  • Discussion of management strategies presented within the guidelines.

Main Results:

  • The guidelines recommend against routine upper urinary tract imaging unless comorbidities exist.
  • Diagnostic cystoscopy is not advised to guide treatment decisions for BPH.
  • Adherence to these principles offers potential for significant cost reduction in BPH care.

Conclusions:

  • Implementing the discussed BPH diagnostic and management strategies, as outlined in the 1994 US clinical guidelines, can yield considerable financial savings.
  • These cost reductions can be achieved while maintaining or improving the quality of care for patients with BPH worldwide.

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...